(Immunotherapy Clinical Trial for COVID 19)...El Centro Regional Medical Center says they will be participating in the trial.

ECRMC says they will be participating in an additional trial to battle COVID 19. The trial, which is run by Corvus Pharmaceuticals, Inc., studies the use of a novel immunotherapy for hospitalized patients with COVID 19. Doctor Christian Tmaszewski will be the lead investigator for ECRMC. He says they have seen a great deal of challenges in COVID 19 treatment, but the potential for new treatments is there and ECRMC is pleased to be able to help study these treatments. The purpose of the trial is to study a novel humanized monocional antibody, designated CPI-006, as an immunotherapy for mild to moderate ill COVID 19 patients that require hospitalization. The overall goal is to determine CPI-006's potential to enhance antibody responses to COVID 19, improve clinical outcomes, and prolong immunity.